MONTGOMERY, Ala., June 3, 2014 /PRNewswire/ -- H2-Pharma, LLC announced today the launch of Fenofibrate 50 mg and 150 mg capsules, an authorized generic version of LIPOFEN®.
LIPOFEN® is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and to increase high-density lipoprotein cholesterol in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
"We are pleased to introduce this authorized generic to the market which offers an alternative to consumers and pharmacists," said Bryce M. Harvey, President of H2-Pharma. "This initial product launch fulfills our goal to add value to our partners existing product portfolios."
H2-Pharma, LLC is a privately-held generic pharmaceutical company focused on the sales and marketing as well as the distribution of generic pharmaceuticals. The Company's primary goal is to bring value to their partners' existing product portfolios by utilizing their extensive industry experience and knowledge. The Company's commitment is to continue to foster innovation within the industry by developing new ideas and programs which will benefit each and every one of their customers.
H2 Pharma sells its product line through major distribution channels, and operates from a cGMP-compliant, VAWD-certified facility. For more information, visit www.h2-pharma.com
CONTACT: Bryce Harvey, 1-334-647-1947, [email protected]
SOURCE H2-Pharma, LLC